1[1]Theroux P,Willerson JT,Armstrong PW.Progress in the treatment of acute coronary syndromes a 50-year perspective(1950～2000)[J].Circulation,2000,102:2～13.
2[2]Pepine CJ.An ischemia-guided approach for risk stratification in the patients with acute coronary syndromes[J].Am J Cardiol,2000,86:27～35.
3[3]Aviles RJ,Askari AT,Lindahl B,et al.Troponin T levels in patients with acute coronary syndromes with or without renal dysfunction[J].N Engl J Med,2002,346:2047～2052.
4[4]Jaffe AS,Ravkilde J,Roberts R,et al.It's time for a change to a troponin standard[J].Circulation,2000,102:1216～1220.
5[5]Gottsauner-Wolf M,Zasmeta G,Hornykewycz S,et al.Plasma levels of C-reative protein after stent implantation[J].Eur Heart J,2000,21:1152～1158.
6[6]Carville DG,Dimitrijevic N,Walsh M,et al.Thrombus precursor protein(TpP):marker of thrombosis early in the pathogenesis of myocardial infarction[J].Clin Chem,1996,42:1537～1541.
7[7]Waters DD,Hsue PY.What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?[J].Am J Cardiol,2001,88:7～16.
8[8]Steg PG,Iung B,Feldman LJ,et al.Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes[J].Heart,2002,88:20～24.
9[9]Ronner E,Boersma E,Laarman GJ,et al.Early angioplasty in acute coronary syndromes with persistent ST-segment elevation improves outcome but increases the need for six-month repeat reveascularization:an analysis of the PURSUIT trail.Platelet glycoprotein Ⅱb/Ⅲa in unstable angina:Receptor Suppression Using Integrilin Therapy[J].J Am Coll Cardiol,2002,39:1924～1929.
10[10]Gilchrist IC,Berkouitz SD,Thompson TD,et al.Heparin dosing and outcome in acute coronary syndromes:The GUSTO-Ⅱb experience.Global use of strategies to open occluded coronary arteries[J].Am Heart J,2002,144:73～80.
